Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists.
